Evodiamine and its nano‐based approaches for enhanced cancer therapy: recent advances and challenges

Abstract

AbstractEvodiamine is a bioactive alkaloid extracted from the Evodia rutaecarpa plant. It has various pharmacological effects including anti‐cancer, anti‐bacterial, anti‐obesity, anti‐neurodegenerative, anti‐depressant, and cardiac protective properties. Evodiamine demonstrates potent anti‐cancer activity by inhibiting the proliferation of cancer cells in vitro and in vivo. Despite the health‐promoting properties of evodiamine, its clinical use is hindered by low water solubility, poor bioavailability, and toxicity. Thus, there is a need to develop alternative drug delivery systems for evodiamine to enhance its solubility, permeability, and stability, as well as to facilitate targeted, prolonged, and controlled drug release. Nanocarriers can increase the therapeutic potential of evodiamine in cancer therapy while reducing adverse side effects. To date, numerous attempts have been made through the development of smart nanocarriers to overcome the drawbacks of evodiamine. This review focuses on the pharmacological applications, anti‐cancer mechanisms, and limitations of evodiamine. Various nanocarriers, including lipid‐based nanoparticles, polymeric nanoparticles, cyclodextrins, and so forth, have been discussed extensively for evodiamine delivery. Nano‐drug delivery systems could increase the solubility, bioavailability, stability, and therapeutic efficacy of evodiamine. This review aims to present a comprehensive and critical evaluation of several nano‐formulations of evodiamine for cancer therapy. © 2024 Society of Chemical Industry.